Cerebrolysin for Alzheimer's disease
Editorial Group: Cochrane Dementia and Cognitive Improvement Group
Published Online: 21 JAN 2009
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Fragoso YD, Dantas DC. Cerebrolysin for Alzheimer's disease (Protocol). Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD003801. DOI: 10.1002/14651858.CD003801.
- Publication Status: Edited (no change to conclusions)
- Published Online: 21 JAN 2009
This is the protocol for a review and there is no abstract. The objectives are as follows:
In vitro and in vivo studies of cerebrolysin in a variety of animal models have shown promising results (Valouskova 1998, Masliah 1999, Veinbergs 2000, Hartbauer 2001). In vitro studies of cultured neurons have shown that cerebrolysin counteracted the neurodegenerative effects of glutamate and free radicals (Hutter-Paier 1996, Hutter-Paier 1988, Windisch 1998). Neurophysiological evaluations have shown that cerebrolysin may enhance brain alpha activity, clinically correlated to better cognitive performance (Alvarez 2000). A variety of clinical trials with Alzheimer patients have now been performed and a systematic review of such trials is necessary. Some of these trials have been mentioned in a recent paper (Rüther 2000).